UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...

Merus announced data from 43 evaluable patients who received the petosemtamab + Keytruda combination. Credit: Smart Calendar via Shutterstock. · Clinical Trials Arena · Smart Calendar via Shutterstock ...

Merus N.V. (NASDAQ:MRUS), a biotechnology company specializing in innovative antibody-based therapies with a market capitalization of $2.75 billion, has garnered significant attention from analysts ...

Biohaven enters a significant research collaboration with Merus, enhancing its capabilities in developing novel bispecific antibody drug conjugates, which could lead to innovative cancer therapies.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...

Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ®, Triclonics ® and ...

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May ...

Merus NV, a clinical-stage immuno-oncology player listed on Nasdaq, remains in the spotlight as investors digest recent clinical data updates on its bispecific antibody pipeline and assess what they ...

Shares of Dutch oncology company Merus NV traded higher after the firm presented early and preclinical data for two full-length, multispecific antibodies, MCLA-158 and zenocutuzumab, to the ...

UTRECHT, The Netherlands, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced ...